在椎体骨髓质子密度脂肪分数MRI中加入肝脏R2*定量可提高骨质疏松预测
纳入107名健康女性,行DXA和化学位移编码3.0-T MRI,测量腰椎骨髓PDFF和肝脏R2*,评估二者联合对骨质减少和骨质疏松的预测价值。PDFF和R2*的OR分别为4.05和4.34,联合R2*后C统计量从0.888升至0.900,NRI为75.6%(p<0.01),提示肝脏R2*可能作为预测骨质减少和骨质疏松的生物标志物。
要点
- 骨髓PDFF和肝脏R2*均与骨质减少/骨质疏松相关,OR分别为4.05和4.34。
- 联合肝脏R2*后预测模型的C统计量从0.888升高至0.900,NRI为75.6%。
- 肝脏R2*测量可重复性好,观察者内和观察者间一致性高。
核心结论
- 在骨髓PDFF和其他传统危险因素基础上加入肝脏R2*可改善对健康女性骨质减少和骨质疏松的预测能力。
研究设计与样本
- 研究纳入2019年6月至2021年1月间107名健康女性,均接受双能X线吸收测定法和化学位移编码3.0-T MRI,测量每个腰椎椎体的PDFF及肝脏各段的R2*。
诊断标准与关键数值
- 骨量减少42例(39.3%),非骨量减少65例(60.7%);PDFF的OR为4.05(95%CI 1.22-13.43),R2*的OR为4.34(95%CI 1.41-13.35);不含R2*的C统计量为0.888(95%CI 0.827-0.950),含R2*的C统计量为0.900(95%CI 0.841-0.960);PDFF与R2*联合的NRI为75.6%(p<0.01)。
临床应用与阅片要点
- 作者认为肝脏R2*有潜力作为健康女性骨质减少和骨质疏松的生物标志物;阅片时可关注骨髓PDFF和肝脏R2*的定量测量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess the predictive value of the combination of bone marrow (BM) proton density fat fraction (PDFF) and liver R2* for osteopenia and osteoporosis and the additional role of liver R2*.
METHODS: A total of 107 healthy women were included between June 2019 and January 2021. Each participant underwent dual-energy X-ray absorptiometry (DXA) and chemical shift-encoded 3.0-T MRI. PDFF measurements were performed for each lumbar vertebral body, and R2* measurements were performed in liver segments. Agreement among measurements was assessed by Bland-Altman analysis. Receiver operating characteristic (ROC) curves were generated to select optimised cut-offs for BM PDFF and liver R2*. Univariable and multivariable logistic regressions were performed. The C statistic and continuous net reclassification improvement (NRI) were adopted to explore the incremental predictive ability of liver R2*.
RESULTS: Bone mass decreased in 42 cases (39.3%) and nonbone mass decreased in 65 cases (60.7%). There were significant differences among the age groups, menopausal status groups, PDFF > 45.0% groups, and R2* > 67.7 groups. Each measurement had good reproducibility. The odds ratios (95% CIs) were 4.05 (1.22-13.43) for PDFF and 4.34 (1.41-13.35) for R2*. The C statistic (95% CI) without R2* was 0.888 (0.827-0.950), and with R2* was 0.900 (0.841-0.960). The NRI resulting from the combination of PDFF and R2* was 75.6% (p < 0.01).
CONCLUSION: The predictive improvement over the use of BM PDFF and other traditional risk factors demonstrates the potential of liver R2* as a biomarker for osteopenia and osteoporosis in healthy women.
KEY POINTS: • Liver R2* is a biomarker for the assessment of osteopenia and osteoporosis. • Liver R2* improved the ability to predict osteopenia and osteoporosis. • The intra- and interobserver measurements showed high agreement.
引用
- Lu, Zhao, Ni, et al. Adding liver R2* quantification to proton density fat fraction MRI of vertebral bone marrow improves the prediction of osteoporosis. Eur Radiol. 2022. PMID: 35610386. doi:10.1007/s00330-022-08861-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。